Drug profile · INN
delandistrogene moxeparvovec
ELEVIDYS
delandistrogene moxeparvovec (ELEVIDYS) is a dystrophin exogenous gene.
Drug details — delandistrogene moxeparvovec
- Class
- Musculo-skeletal system (M09)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
delandistrogene moxeparvovec (ELEVIDYS) is a dystrophin exogenous gene.
Key facts
Mechanism of action
Dystrophin exogenous gene
Primary target: Dystrophin
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Recent coverage
Roche's Elevidys: A New Hope for DMD Gene Therapy Approval
Roche aims for EMA approval of Elevidys, a gene therapy for DMD, amidst regulatory challenges. This article analyzes the implications for investors and pharma teams.
Roche's Elevidys Study Launch: Navigating EU Rejection
Roche is set to launch another study for Elevidys following the EMA's rejection. This article analyzes the implications for investors and pharma teams.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is delandistrogene moxeparvovec?
delandistrogene moxeparvovec (ELEVIDYS) is a dystrophin exogenous gene.
What is the brand name for delandistrogene moxeparvovec?
ELEVIDYS is a marketed brand name for delandistrogene moxeparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.